Clinical trial

A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

NCT03145909

Study summary

ClinicalTrials.gov

A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention ABBV-176 Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2017-07-03

PhasePHASE1

Conditions

Advanced Solid Tumors Cancerunresolved

Interventions

ABBV-176DRUG

Sponsors & collaborators

AbbVielead sponsor

Mapped research locations

St LouisMissouri, United States1 MadridSpain1 New HavenConnecticut, United States1 Salt Lake CityUtah, United States1 Kansas CityMissouri, United States1 ScottsdaleArizona, United States1 DuarteCalifornia, United States1 New BrunswickNew Jersey, United States1 South BrisbaneQueensland, Australia1 RandwickNew South Wales, Australia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03145909 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.